Structures by: Steele G.
Total: 8
Famotidine
C8H15N7O2S3
Journal of Applied Crystallography (2002) 35, 4 443-454
a=17.6547(4)Å b=5.29320(10)Å c=18.2590(3)Å
α=90.0° β=123.5580(10)° γ=90.0°
N-[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]- 3-[2-(2-naphthalen-1-ylethoxy)ethylsulfonyl]propylaminium benzoate
C26H31N2O5S2,C7H5O2
Acta Crystallographica Section E (2004) 60, 10 o1751-o1753
a=7.63122(17)Å b=13.6673(3)Å c=15.8058(5)Å
α=84.385(2)° β=87.4653(19)° γ=75.7135(13)°
Remacemide
C17H20N2O
Crystal Growth & Design (2005) 5, 2 427
a=8.9200(10)Å b=16.524(2)Å c=9.8570(10)Å
α=90.00° β=93.836(10)° γ=90.00°
Remacemide nitrate
C17H21N2O1,N1O3
Crystal Growth & Design (2005) 5, 2 427
a=11.724(4)Å b=8.932(4)Å c=15.872(4)Å
α=90.00° β=95.93(2)° γ=90.00°
Remacemide xinafoate
C17H21N2O1,C11H7O3
Crystal Growth & Design (2005) 5, 2 427
a=11.9187(10)Å b=31.801(3)Å c=7.9304(7)Å
α=90.00° β=128.382(2)° γ=90.00°
Remacemide acetate
C17H21N2O1,C2H3O2
Crystal Growth & Design (2005) 5, 2 427
a=15.4018(3)Å b=6.7683(1)Å c=17.3531(3)Å
α=90.0° β=93.13(1)° γ=90.0°
Remacemide napsilate
C17H21N2O1,C10H7SO3,0.4(C2H6O1),0.5(H2O1)
Crystal Growth & Design (2005) 5, 2 427
a=9.7297(4)Å b=14.4323(3)Å c=19.4269(4)Å
α=104.859(2)° β=90.490(2)° γ=95.546(2)°
Remacemide hydrochloride salt
C17H21N2O,Cl
Crystal Growth & Design (2005) 5, 2 427
a=10.660(2)Å b=8.712(2)Å c=17.624(3)Å
α=90.00° β=90.770(18)° γ=90.00°